The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The IMMULAB trial: A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early stage hepatocellular carcinoma (HCC).
 
Arndt Vogel
Honoraria - Amgen; Bristol-Myers Squibb; Ipsen; Janssen; Lilly; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Baxalta; Bayer; BTG; Eisai; IPSEN; Lilly; Novartis; Pierre Fabre; Roche
Research Funding - Novartis
Travel, Accommodations, Expenses - Bayer; Ipsen; Roche
 
Thorsten Oliver Goetze
Consulting or Advisory Role - Bayer; Lilly; MSD Oncology; Roche; SERVIER
Speakers' Bureau - Lilly
Research Funding - Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe (Inst); Gemeinsamer Bundesausschuss
 
Guido Hausner
No Relationships to Disclose
 
Michael Geißler
No Relationships to Disclose
 
Gabriele Margareta Siegler
Honoraria - Aurikamed; Deutsche Röntgengesellschaft; Eisai; Janssen-Cilag; medizinwelten services GmbH; Roche; Shire
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Janssen-Cilag
Research Funding - Beigene (Inst); Celgene (Inst); Isofol Medical (Inst); MOLOGEN (Inst); Novartis (Inst); Nutricia (Inst); Roche (Inst); Roche/Genentech (Inst); Sanofi (Inst); Servier (Inst)
Travel, Accommodations, Expenses - Lilly
 
Ludwig Fischer von Weikersthal
No Relationships to Disclose
 
Angelika M. R. Kestler
No Relationships to Disclose
 
Matthias Kleiß
No Relationships to Disclose
 
Tobias Müller
No Relationships to Disclose
 
Andreas Teufel
No Relationships to Disclose
 
Jens Marquardt
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Ipsen; Janssen; Merz GmbH; MSD Oncology; Roche
Research Funding - Bayer (Inst); Leap Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; Ipsen; Merz GmbH
 
Maria A Gonzalez-Carmona
No Relationships to Disclose
 
Daniel Wilhelm Mueller
No Relationships to Disclose
 
Regina Eickhoff
No Relationships to Disclose
 
Enrico N. de Toni
Honoraria - Bristol-Myers Squibb; Falk Pharma
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Lilly; Pfizer; Roche
Research Funding - ArQule; AstraZeneca; Bayer; Bristol-Myers Squibb; Lilly; Roche
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Bayer; Bristol-Myers Squibb; Celsion; Roche
 
Oliver Waidmann
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Eisai; Ipsen; Merck; Novartis; Roche; Shire
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Eisai; Incyte; Ipsen; Merck Serono; MSD; Novartis; Roche; SERVIER; Shire
Research Funding - Basilea; Incyte; Medac; Merck Serono; MSD
Travel, Accommodations, Expenses - Abbvie; Bayer; Bristol-Myers Squibb; Gilead Sciences; Ipsen; Medac; Merck
 
Salah-Eddin Al-Batran
Stock and Other Ownership Interests - Institut für Klinische Krebsforschung GmbH
Consulting or Advisory Role - Bristol-Myers Squibb; Immutep; Lilly; MacroGenics; Merck Sharp & Dohme
Speakers' Bureau - AIO gGmbH; Bristol-Myers Squibb; Lilly; MCI Group
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celgene; Eurozyto; Federal Ministry of Education and Research; German Cancer Aid; German Research Foundation; Hospira; Immutep; Ipsen; Lilly; Medac; MSD Sharp & Dohme; Roche; Sanofi; Vifor Pharma